Annual report pursuant to Section 13 and 15(d)

Composition of Certain Financial Statement Captions (Details)

v2.4.0.8
Composition of Certain Financial Statement Captions (Details) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Accounts receivable, net:    
Accounts receivable $ 21,652 $ 21,636
Less: allowance for doubtful accounts (1,885) (474)
Accounts receivable, net 19,767 [1] 21,162 [1]
Inventories, net:    
Finished products 13,374 17,963
Work in-process 1,350 688
Raw materials 4,132 4,923
Less: inventory reserve (777) (1,313)
Inventory, net 18,079 [1] 22,261 [1]
Prepaid expense and other assets:    
Prepaid supplies 945 443
Prepaid insurance 892 301
Pharmsynthez Note Receivable and Purchase Option 6,151 0
Other receivables 1,985 886
Taxes recoverable 3,458 1,493
Other 5,653 4,750
Prepaid expenses and other current assets 19,084 [1] 7,873 [1]
Property, plant and equipment, net:    
Machinery and equipment 11,656 7,984
Building 3,615 3,457
Land 2,666 2,619
Furniture and fixtures 2,051 1,908
Software 807 853
Leasehold improvements 3,107 2,616
Construction in process 489 0
Less: accumulated depreciation (7,364) (3,732)
Property, plant and equipment, net 17,027 15,705
Investment properties, net:    
Building 0 384
Land 0 450
Less: accumulated depreciation 0 (13)
Investment Properties Net 0 821
Intangible assets, net:    
Less: accumulated amortization 24,403 14,072
Intangible assets, net 74,533 [1] 84,238 [1]
Accrued expenses:    
Taxes payable 702 1,614
Deferred revenue 7,639 1,518
Clinical trials 3,342 50
Professional fees 402 675
Employee benefits 4,399 3,319
Deferred acquisition payments, net of discount 5,465 6,172
Contingent consideration 28,047 5,126
Interest payable related to the Notes 0 0
Other 15,878 6,182
Accrued expenses 65,874 [1] 24,656 [1]
Other long-term liabilities:    
Deferred acquisition payments, net of discount 0 3,931
Mortgages and other debts payable 3,270 5,150
Deferred tax liabilities 166,435 9,777
Other, including deferred revenue 1,509 380
Other long-term liabilities 214,775 [1] 34,168 [1]
Cytochroma [Member]
   
Other long-term liabilities:    
Contingent consideration 34,401 0
Farmadiet [Member]
   
Other long-term liabilities:    
Contingent consideration 504 532
OPKO Diagnostics [Member]
   
Other long-term liabilities:    
Contingent consideration 8,340 11,310
FineTech [Member]
   
Other long-term liabilities:    
Contingent consideration 0 2,578
CURNA [Member]
   
Other long-term liabilities:    
Contingent consideration 316 510
Technologies [Member]
   
Intangible assets, net:    
Intangible assets 51,660 52,810
Customer relationships [Member]
   
Intangible assets, net:    
Intangible assets 22,725 23,088
Product registrations [Member]
   
Intangible assets, net:    
Intangible assets 9,692 9,637
Tradenames [Member]
   
Intangible assets, net:    
Intangible assets 3,669 3,746
Covenants not to compete [Member]
   
Intangible assets, net:    
Intangible assets 8,671 8,662
Other [Member]
   
Intangible assets, net:    
Intangible assets $ 2,519 $ 367
[1] As of December 31, 2013 and 2012, total assets include $6.7 million and $5.6 million, respectively, and total liabilities include $10.4 million and $5.5 million, respectively related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and the holders of SciVac’s consolidated liabilities have no recourse against us. Refer to Note 3.